Table 1.
Characterization of patients with Alzheimer’s disease and healthy normal control subjects
| AD | Healthy normal control subjects | |
|---|---|---|
| Total sample number | 24 | 29 |
| Sex | ||
| Female | 13 (54.2%) | 16 (55.2%) |
| Male | 11 (45.8%) | 13 (44.8%) |
| Age, years (SD) | 67.6 (±7.4) | 62.4 (±5.7) |
| Education, years (SD) | 13.1 (±3.9) | 13.2 (±3.5) |
| CDR-SOB, mean | 6.35 | 0.03 |
| MMSE score, mean | 17.7 | 29.03 |
| ApoE ε4, % | 47.8 | 21.7 |
| Note test | 1 | 0 |
| Number of plasma samples | 24 | 29 |
| CSF markers | 23 | 28 |
| Aβ42, pg/ml, mean (SD) | 258.6 (±70.8) | 464.8 (±114.4) |
| p-Tau, pg/ml, mean (SD) | 58.6 (±18.6) | 28.0 (±14.3) |
| t-Tau, pg/ml, mean (SD) | 132.1 (±61.8) | 62.1 (±20.3) |
| PiB-PET number | 23 | 28 |
| Mean SUVR | 1.57 | 1.14 |
| FDG-PET number | 18 | 28 |
| Mean SUVR | 0.9 | 1.06 |
Abbreviations: Aβ 42 Amyloid-β 1–42 peptide, AD Alzheimer’s disease, ApoE Apolipoprotein E, CDR-SOB Clinical Dementia Rating Sum of Boxes, CSF Cerebrospinal fluid, FDG 18F-fluorodeoxyglucose, MMSE Mini Mental State Examination, PET Positron emission tomography, PiB 11C-Pittsburgh compound B, p-Tau Phosphorylated tau protein, SUVR Standardized uptake value ratio, t-Tau Total tau protein